Delcath's Chemosat Hepatic Delivery System Shows Overall Response Rate Of 60.5% In Eye Cancer That Spreads To Liver


Delcath Systems Inc's DCTH single-institution retrospective study data on CHEMOSAT Hepatic Delivery System for liver dominant metastatic uveal melanoma (mUM) were published in the journal Melanoma Research.

  • 41 of 81 (50.6%) patients had received other treatments, either systemic or liver-directed, before percutaneous hepatic perfusion (PHP) treatment. 250 PHP procedures were performed in 81 patients. 
  • The Company's PHP system is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
  • The PHP system is being developed under the tradename, Hepzato Kit.
  • Related: Delcath Systems Reveals Initial Survival Data From Ocular Melanoma Trial.
  • The analysis demonstrated a hepatic disease control rate of 88.9% (72/81), a hepatic response rate of 66.7%, and an overall response rate of 60.5%.
  • After a median follow-up of 12.9 months, median overall progression-free survival (PFS) and median overall survival (OS) were 8.4 and 14.9 months, respectively.
  • Treatment-emergent adverse events of Grade 3 or 4 occurred in 23 patients, anemia observed in 11 patients (13.3%), and thrombocytopenia in 10 patients (12%). 
  • There were no fatal treatment-related adverse events.
  • Price Action: DCTH shares closed at $6.99 on Thursday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!